Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Official title

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)

Study identification

NCT ID

NCT04267848

Recruitment status

Recruiting

Study type

Interventional

Phase

Phase 3

Lead sponsor

National Cancer Institute (NCI)

NIH

Enrollment

1,210 participants

Conditions and interventions

Eligibility (public fields only)

Age range

18 Years and older

Sex

All

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Jun 15, 2020

Primary completion

Jan 30, 2027

Completion

Jan 30, 2027

Last update posted

May 7, 2026

2020 – 2027

United States locations

U.S. sites

1150

U.S. states

49

U.S. cities

750

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.